ES2541476T3 - Sacarosas octasulfatos de magnesio, su preparación y sus aplicaciones farmacéuticas y cosméticas - Google Patents

Sacarosas octasulfatos de magnesio, su preparación y sus aplicaciones farmacéuticas y cosméticas Download PDF

Info

Publication number: ES2541476T3
Authority: ES; Spain
Prior art keywords: sos; compound; sucrose; sucrose octasulfate; octasulfate
Prior art date: 2011-05-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES12724633.8T

Other languages

English (en)

Spanish (es)

Inventor

Séverine JEULIN

Hélène HERNANDEZ-PIGEON

Luc Aguilar

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pierre Fabre Dermo Cosmetique SA

Original Assignee

Pierre Fabre Dermo Cosmetique SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-05-31

Filing date

2012-05-31

Publication date

2015-07-20

2012-05-31 Application filed by Pierre Fabre Dermo Cosmetique SA filed Critical Pierre Fabre Dermo Cosmetique SA

2015-07-20 Application granted granted Critical

2015-07-20 Publication of ES2541476T3 publication Critical patent/ES2541476T3/es

Status Active legal-status Critical Current

2032-05-31 Anticipated expiration legal-status Critical

Links

229930006000 Sucrose Natural products 0.000 title description 28
239000005720 sucrose Substances 0.000 title description 28
239000002537 cosmetic Substances 0.000 title description 9
-1 Sucrose sulfate octasulfates Chemical class 0.000 title description 7
238000002360 preparation method Methods 0.000 title description 5
150000001875 compounds Chemical class 0.000 claims abstract description 44
230000035876 healing Effects 0.000 claims abstract description 18
208000015181 infectious disease Diseases 0.000 claims abstract description 9
230000000813 microbial effect Effects 0.000 claims abstract description 8
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 4
230000002265 prevention Effects 0.000 claims abstract 3
208000027418 Wounds and injury Diseases 0.000 claims description 14
206010052428 Wound Diseases 0.000 claims description 13
231100000241 scar Toxicity 0.000 claims description 9
230000001684 chronic effect Effects 0.000 claims description 5
230000002496 gastric effect Effects 0.000 claims description 5
230000001154 acute effect Effects 0.000 claims description 4
239000000546 pharmaceutical excipient Substances 0.000 claims description 4
206010015150 Erythema Diseases 0.000 claims description 3
208000025865 Ulcer Diseases 0.000 claims description 3
208000010668 atopic eczema Diseases 0.000 claims description 3
238000001356 surgical procedure Methods 0.000 claims description 3
208000002874 Acne Vulgaris Diseases 0.000 claims description 2
201000004624 Dermatitis Diseases 0.000 claims description 2
208000004210 Pressure Ulcer Diseases 0.000 claims description 2
206010042496 Sunburn Diseases 0.000 claims description 2
206010000496 acne Diseases 0.000 claims description 2
208000007287 cheilitis Diseases 0.000 claims description 2
238000000315 cryotherapy Methods 0.000 claims description 2
206010012601 diabetes mellitus Diseases 0.000 claims description 2
231100000321 erythema Toxicity 0.000 claims description 2
230000007794 irritation Effects 0.000 claims description 2
231100000397 ulcer Toxicity 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims 2
208000020670 canker sore Diseases 0.000 claims 1
WEPNHBQBLCNOBB-FZJVNAOYSA-N sucrose octasulfate Chemical compound OS(=O)(=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@H](COS(=O)(=O)O)O[C@]1(COS(O)(=O)=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](COS(O)(=O)=O)O1 WEPNHBQBLCNOBB-FZJVNAOYSA-N 0.000 description 53
239000000203 mixture Substances 0.000 description 35
239000011777 magnesium Substances 0.000 description 34
210000002510 keratinocyte Anatomy 0.000 description 33
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 26
239000000243 solution Substances 0.000 description 20
229910052749 magnesium Inorganic materials 0.000 description 19
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 18
239000002253 acid Substances 0.000 description 18
108090000623 proteins and genes Proteins 0.000 description 18
239000011734 sodium Substances 0.000 description 17
210000003491 skin Anatomy 0.000 description 16
150000002632 lipids Chemical class 0.000 description 15
230000004069 differentiation Effects 0.000 description 14
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
210000004027 cell Anatomy 0.000 description 12
230000000694 effects Effects 0.000 description 12
159000000003 magnesium salts Chemical class 0.000 description 12
238000000034 method Methods 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
230000000845 anti-microbial effect Effects 0.000 description 11
102000004169 proteins and genes Human genes 0.000 description 11
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 10
102000044503 Antimicrobial Peptides Human genes 0.000 description 9
108700042778 Antimicrobial Peptides Proteins 0.000 description 9
239000007864 aqueous solution Substances 0.000 description 9
230000004888 barrier function Effects 0.000 description 9
230000012292 cell migration Effects 0.000 description 9
108020004999 messenger RNA Proteins 0.000 description 9
102100026887 Beta-defensin 103 Human genes 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
102100031673 Corneodesmosin Human genes 0.000 description 7
101710139375 Corneodesmosin Proteins 0.000 description 7
101000912247 Homo sapiens Beta-defensin 103 Proteins 0.000 description 7
102100031784 Loricrin Human genes 0.000 description 7
102100040312 Ribonuclease 7 Human genes 0.000 description 7
108010085025 Ribonuclease 7 Proteins 0.000 description 7
108010079309 loricrin Proteins 0.000 description 7
230000005012 migration Effects 0.000 description 7
238000013508 migration Methods 0.000 description 7
XISWAUUBQBEDFB-QRDGSJRXSA-F octapotassium;[(2r,3r,4s,5r,6r)-2-[(2s,3s,4r,5r)-3,4-disulfonatooxy-2,5-bis(sulfonatooxymethyl)oxolan-2-yl]oxy-3,5-disulfonatooxy-6-(sulfonatooxymethyl)oxan-4-yl] sulfate Chemical compound [K+].[K+].[K+].[K+].[K+].[K+].[K+].[K+].[O-]S(=O)(=O)O[C@H]1[C@H](OS([O-])(=O)=O)[C@@H](COS(=O)(=O)[O-])O[C@@]1(COS([O-])(=O)=O)O[C@@H]1[C@H](OS([O-])(=O)=O)[C@@H](OS([O-])(=O)=O)[C@H](OS([O-])(=O)=O)[C@@H](COS([O-])(=O)=O)O1 XISWAUUBQBEDFB-QRDGSJRXSA-F 0.000 description 7
229920001542 oligosaccharide Polymers 0.000 description 7
150000002482 oligosaccharides Chemical class 0.000 description 7
102100024502 Ceramide glucosyltransferase Human genes 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
101000981050 Homo sapiens Ceramide glucosyltransferase Proteins 0.000 description 6
ONXFNTKJSUVHDZ-UHFFFAOYSA-A S(=O)(=O)([O-])[O-].S(=O)(=O)([O-])[O-].S(=O)(=O)([O-])[O-].S(=O)(=O)([O-])[O-].S(=O)(=O)([O-])[O-].S(=O)(=O)([O-])[O-].S(=O)(=O)([O-])[O-].S(=O)(=O)([O-])[O-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2] Chemical compound S(=O)(=O)([O-])[O-].S(=O)(=O)([O-])[O-].S(=O)(=O)([O-])[O-].S(=O)(=O)([O-])[O-].S(=O)(=O)([O-])[O-].S(=O)(=O)([O-])[O-].S(=O)(=O)([O-])[O-].S(=O)(=O)([O-])[O-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2] ONXFNTKJSUVHDZ-UHFFFAOYSA-A 0.000 description 6
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 6
239000011575 calcium Substances 0.000 description 6
229910052791 calcium Inorganic materials 0.000 description 6
230000006870 function Effects 0.000 description 6
239000013642 negative control Substances 0.000 description 6
239000000047 product Substances 0.000 description 6
239000007787 solid Substances 0.000 description 6
239000002904 solvent Substances 0.000 description 6
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
101000884714 Homo sapiens Beta-defensin 4A Proteins 0.000 description 5
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
206010061218 Inflammation Diseases 0.000 description 5
WXOMTJVVIMOXJL-BOBFKVMVSA-A O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O WXOMTJVVIMOXJL-BOBFKVMVSA-A 0.000 description 5
210000000736 corneocyte Anatomy 0.000 description 5
210000002615 epidermis Anatomy 0.000 description 5
230000006698 induction Effects 0.000 description 5
230000004054 inflammatory process Effects 0.000 description 5
229910001629 magnesium chloride Inorganic materials 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
230000008591 skin barrier function Effects 0.000 description 5
229910052708 sodium Inorganic materials 0.000 description 5
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 5
241000894006 Bacteria Species 0.000 description 4
102100038326 Beta-defensin 4A Human genes 0.000 description 4
208000032544 Cicatrix Diseases 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
102100028314 Filaggrin Human genes 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
230000024245 cell differentiation Effects 0.000 description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
238000004090 dissolution Methods 0.000 description 4
230000036571 hydration Effects 0.000 description 4
238000006703 hydration reaction Methods 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
CPRSOZZDECJZKH-QRDGSJRXSA-F octasodium;[(2r,3r,4s,5r,6r)-2-[(2s,3s,4r,5r)-3,4-disulfonatooxy-2,5-bis(sulfonatooxymethyl)oxolan-2-yl]oxy-3,5-disulfonatooxy-6-(sulfonatooxymethyl)oxan-4-yl] sulfate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)O[C@H]1[C@H](OS([O-])(=O)=O)[C@@H](COS(=O)(=O)[O-])O[C@@]1(COS([O-])(=O)=O)O[C@@H]1[C@H](OS([O-])(=O)=O)[C@@H](OS([O-])(=O)=O)[C@H](OS([O-])(=O)=O)[C@@H](COS([O-])(=O)=O)O1 CPRSOZZDECJZKH-QRDGSJRXSA-F 0.000 description 4
239000013641 positive control Substances 0.000 description 4
238000011084 recovery Methods 0.000 description 4
230000037387 scars Effects 0.000 description 4
229960004291 sucralfate Drugs 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 3
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
102100023519 Cornifin-A Human genes 0.000 description 3
102100030291 Cornifin-B Human genes 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
101000912243 Homo sapiens Beta-defensin 104 Proteins 0.000 description 3
101000828732 Homo sapiens Cornifin-A Proteins 0.000 description 3
101000702152 Homo sapiens Cornifin-B Proteins 0.000 description 3
102000011782 Keratins Human genes 0.000 description 3
108010076876 Keratins Proteins 0.000 description 3
102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 description 3
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000004568 cement Substances 0.000 description 3
229940106189 ceramide Drugs 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000005342 ion exchange Methods 0.000 description 3
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 3
239000000347 magnesium hydroxide Substances 0.000 description 3
229910001862 magnesium hydroxide Inorganic materials 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
210000004400 mucous membrane Anatomy 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
239000003910 polypeptide antibiotic agent Substances 0.000 description 3
229910052700 potassium Inorganic materials 0.000 description 3
239000011591 potassium Substances 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
239000002243 precursor Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
230000037390 scarring Effects 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
108010012236 Chemokines Proteins 0.000 description 2
102000019034 Chemokines Human genes 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
101710088660 Filaggrin Proteins 0.000 description 2
229930091371 Fructose Natural products 0.000 description 2
239000005715 Fructose Substances 0.000 description 2
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
241000233866 Fungi Species 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
108010017544 Glucosylceramidase Proteins 0.000 description 2
101000976051 Homo sapiens Involucrin Proteins 0.000 description 2
102100023913 Involucrin Human genes 0.000 description 2
CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
101150057849 Padi1 gene Proteins 0.000 description 2
241000532838 Platypus Species 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical compound OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
102100030944 Protein-glutamine gamma-glutamyltransferase K Human genes 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
SGSMKCVVBIKECH-UHFFFAOYSA-N S(=O)(=O)(O)O.S(=O)(=O)(O)O.S(=O)(=O)(O)O.S(=O)(=O)(O)O.S(=O)(=O)(O)O.S(=O)(=O)(O)O.S(=O)(=O)(O)O.S(=O)(=O)(O)O.S(=O)(=O)(O)O Chemical compound S(=O)(=O)(O)O.S(=O)(=O)(O)O.S(=O)(=O)(O)O.S(=O)(=O)(O)O.S(=O)(=O)(O)O.S(=O)(=O)(O)O.S(=O)(=O)(O)O.S(=O)(=O)(O)O.S(=O)(=O)(O)O SGSMKCVVBIKECH-UHFFFAOYSA-N 0.000 description 2
241000700605 Viruses Species 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
230000002225 anti-radical effect Effects 0.000 description 2
230000002421 anti-septic effect Effects 0.000 description 2
239000002585 base Substances 0.000 description 2
102000012265 beta-defensin Human genes 0.000 description 2
108050002883 beta-defensin Proteins 0.000 description 2
239000012620 biological material Substances 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
235000011148 calcium chloride Nutrition 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
239000003729 cation exchange resin Substances 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
229920001429 chelating resin Polymers 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
238000009833 condensation Methods 0.000 description 2
230000005494 condensation Effects 0.000 description 2
239000013078 crystal Substances 0.000 description 2
230000007123 defense Effects 0.000 description 2
239000003814 drug Substances 0.000 description 2
210000000981 epithelium Anatomy 0.000 description 2
238000004299 exfoliation Methods 0.000 description 2
238000000605 extraction Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
235000021588 free fatty acids Nutrition 0.000 description 2
239000008103 glucose Substances 0.000 description 2
150000002305 glucosylceramides Chemical class 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
239000013003 healing agent Substances 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000015788 innate immune response Effects 0.000 description 2
230000029774 keratinocyte migration Effects 0.000 description 2
244000005700 microbiome Species 0.000 description 2
238000010232 migration assay Methods 0.000 description 2
VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
229940037201 oris Drugs 0.000 description 2
230000007170 pathology Effects 0.000 description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
239000000843 powder Substances 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
102000001235 protein arginine deiminase Human genes 0.000 description 2
108060006632 protein arginine deiminase Proteins 0.000 description 2
230000008439 repair process Effects 0.000 description 2
239000012266 salt solution Substances 0.000 description 2
235000021309 simple sugar Nutrition 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
108010058734 transglutaminase 1 Proteins 0.000 description 2
230000036642 wellbeing Effects 0.000 description 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
108010087765 Antipain Proteins 0.000 description 1
101100272964 Arabidopsis thaliana CYP71B15 gene Proteins 0.000 description 1
101710125296 Beta-defensin 3 Proteins 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
208000035484 Cellulite Diseases 0.000 description 1
102000044956 Ceramide glucosyltransferases Human genes 0.000 description 1
102000001327 Chemokine CCL5 Human genes 0.000 description 1
108010055166 Chemokine CCL5 Proteins 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
102100023795 Elafin Human genes 0.000 description 1
108010015972 Elafin Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
206010016334 Feeling hot Diseases 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
102100020871 Forkhead box protein G1 Human genes 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
101000590281 Homo sapiens 26S proteasome non-ATPase regulatory subunit 14 Proteins 0.000 description 1
101000827746 Homo sapiens Fibroblast growth factor receptor 1 Proteins 0.000 description 1
101000917159 Homo sapiens Filaggrin Proteins 0.000 description 1
101000931525 Homo sapiens Forkhead box protein G1 Proteins 0.000 description 1
101001114059 Homo sapiens Protein-arginine deiminase type-1 Proteins 0.000 description 1
102000004157 Hydrolases Human genes 0.000 description 1
108090000604 Hydrolases Proteins 0.000 description 1
102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
102100023970 Keratin, type I cytoskeletal 10 Human genes 0.000 description 1
102100022905 Keratin, type II cytoskeletal 1 Human genes 0.000 description 1
108010070514 Keratin-1 Proteins 0.000 description 1
108010065038 Keratin-10 Proteins 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
102000004882 Lipase Human genes 0.000 description 1
108090001060 Lipase Proteins 0.000 description 1
239000004367 Lipase Substances 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
244000062730 Melissa officinalis Species 0.000 description 1
235000010654 Melissa officinalis Nutrition 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
239000004909 Moisturizer Substances 0.000 description 1
206010065764 Mucosal infection Diseases 0.000 description 1
101150030164 PADI3 gene Proteins 0.000 description 1
235000021319 Palmitoleic acid Nutrition 0.000 description 1
108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
206010049752 Peau d'orange Diseases 0.000 description 1
102100023222 Protein-arginine deiminase type-1 Human genes 0.000 description 1
102100035734 Protein-arginine deiminase type-3 Human genes 0.000 description 1
206010063562 Radiation skin injury Diseases 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
206010040925 Skin striae Diseases 0.000 description 1
206010040954 Skin wrinkling Diseases 0.000 description 1
108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
208000031439 Striae Distensae Diseases 0.000 description 1
102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
101800004564 Transforming growth factor alpha Proteins 0.000 description 1
108060008539 Transglutaminase Proteins 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
239000000061 acid fraction Substances 0.000 description 1
102000010126 acid sphingomyelin phosphodiesterase activity proteins Human genes 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000003044 adaptive effect Effects 0.000 description 1
230000033289 adaptive immune response Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
230000016571 aggressive behavior Effects 0.000 description 1
208000037883 airway inflammation Diseases 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
231100000360 alopecia Toxicity 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
MBPDDAGACPZDAA-UHFFFAOYSA-K aluminum hydrogen sulfate sulfuric acid sulfate Chemical compound [Al+3].OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.OS([O-])(=O)=O.[O-]S([O-])(=O)=O MBPDDAGACPZDAA-UHFFFAOYSA-K 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
229940064004 antiseptic throat preparations Drugs 0.000 description 1
208000002399 aphthous stomatitis Diseases 0.000 description 1
230000003385 bacteriostatic effect Effects 0.000 description 1
210000002469 basement membrane Anatomy 0.000 description 1
230000003796 beauty Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
GEHJBWKLJVFKPS-UHFFFAOYSA-N bromochloroacetic acid Chemical compound OC(=O)C(Cl)Br GEHJBWKLJVFKPS-UHFFFAOYSA-N 0.000 description 1
230000001914 calming effect Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
108060001132 cathelicidin Proteins 0.000 description 1
102000014509 cathelicidin Human genes 0.000 description 1
230000009087 cell motility Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
230000036232 cellulite Effects 0.000 description 1
108091000114 ceramide glucosyltransferase Proteins 0.000 description 1
150000001783 ceramides Chemical class 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
230000003399 chemotactic effect Effects 0.000 description 1
230000035605 chemotaxis Effects 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
238000007596 consolidation process Methods 0.000 description 1
239000010949 copper Substances 0.000 description 1
229910000365 copper sulfate Inorganic materials 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
230000006003 cornification Effects 0.000 description 1
238000002316 cosmetic surgery Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000010908 decantation Methods 0.000 description 1
230000004040 defense response to microbe Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
210000002249 digestive system Anatomy 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
230000035622 drinking Effects 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
MDCUNMLZLNGCQA-HWOAGHQOSA-N elafin Chemical compound N([C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]2CSSC[C@H]3C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CSSC[C@H]4C(=O)N5CCC[C@H]5C(=O)NCC(=O)N[C@H](C(N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]5N(CCC5)C(=O)[C@H]5N(CCC5)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC2=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N4)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N3)=O)[C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N MDCUNMLZLNGCQA-HWOAGHQOSA-N 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
230000010393 epithelial cell migration Effects 0.000 description 1
238000000105 evaporative light scattering detection Methods 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
238000005187 foaming Methods 0.000 description 1
239000011888 foil Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000012010 growth Effects 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
YQYLUTFBYMLTFA-UHFFFAOYSA-A hexadecasodium;octasulfate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O YQYLUTFBYMLTFA-UHFFFAOYSA-A 0.000 description 1
102000049262 human DEFB4A Human genes 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000007124 immune defense Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000008611 intercellular interaction Effects 0.000 description 1
210000003963 intermediate filament Anatomy 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
108010028309 kalinin Proteins 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000000865 liniment Substances 0.000 description 1
235000019421 lipase Nutrition 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 1
229910001623 magnesium bromide Inorganic materials 0.000 description 1
229910001607 magnesium mineral Inorganic materials 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
230000001333 moisturizer Effects 0.000 description 1
210000002200 mouth mucosa Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
235000021313 oleic acid Nutrition 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid group Chemical class C(CCCCCCC\C=C/CCCCCC)(=O)O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
239000002304 perfume Substances 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000000049 pigment Substances 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000001012 protector Effects 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
238000011002 quantification Methods 0.000 description 1
208000006934 radiodermatitis Diseases 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
238000003753 real-time PCR Methods 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000004044 response Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000004739 secretory vesicle Anatomy 0.000 description 1
230000009759 skin aging Effects 0.000 description 1
230000037067 skin hydration Effects 0.000 description 1
241000894007 species Species 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
210000000434 stratum corneum Anatomy 0.000 description 1
210000000498 stratum granulosum Anatomy 0.000 description 1
150000003445 sucroses Chemical class 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
239000003760 tallow Substances 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
102000003601 transglutaminase Human genes 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1
230000029663 wound healing Effects 0.000 description 1
230000037303 wrinkles Effects 0.000 description 1
NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
229910000368 zinc sulfate Inorganic materials 0.000 description 1
229960001763 zinc sulfate Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/08—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium or tellurium
- C07H5/10—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium or tellurium to sulfur

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Dermatology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Birds (AREA)
Gerontology & Geriatric Medicine (AREA)
Oncology (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Cosmetics (AREA)
Saccharide Compounds (AREA)

ES12724633.8T 2011-05-31 2012-05-31 Sacarosas octasulfatos de magnesio, su preparación y sus aplicaciones farmacéuticas y cosméticas Active ES2541476T3 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
FR1154752A FR2975993B1 (fr)	2011-05-31	2011-05-31	Sucroses octasulfates de magnesium, leur preparation et leurs applications pharmaceutiques et cosmetiques
FR1154752		2011-05-31
PCT/EP2012/060211 WO2012163997A1 (fr)	2011-05-31	2012-05-31	Sucroses octasulfates de magnesium, leur preparation et leurs applications pharmaceutiques et cosmetiques

Publications (1)

Publication Number	Publication Date
ES2541476T3 true ES2541476T3 (es)	2015-07-20

Family

ID=46197271

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES12724633.8T Active ES2541476T3 (es)	2011-05-31	2012-05-31	Sacarosas octasulfatos de magnesio, su preparación y sus aplicaciones farmacéuticas y cosméticas

Country Status (8)

Country	Link
US (1)	US9562065B2 (pl)
EP (1)	EP2714705B1 (pl)
JP (1)	JP5998211B2 (pl)
ES (1)	ES2541476T3 (pl)
FR (1)	FR2975993B1 (pl)
PL (1)	PL2714705T3 (pl)
PT (1)	PT2714705E (pl)
WO (1)	WO2012163997A1 (pl)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR1390007A (fr)	1964-04-13	1965-02-19		Plage permettant d'intégrer sur un disque un enregistrement publicitaire ou autre
US4098995A (en) *	1976-07-12	1978-07-04	American Cyanamid Company	Polygalactosido-sucrose poly(h-)sulfate salts
AU607690B2 (en)	1985-12-24	1991-03-14	Marion Laboratories, Inc.	Use of synthetic sulfated saccharides to enhance wound healing
DK505488D0 (da) *	1987-12-21	1988-09-09	Bar Shalom Daniel	Middel og anvendelse af samme
US5916880A (en) *	1987-12-21	1999-06-29	Bukh Meditec A/S	Reduction of skin wrinkling using sulphated sugars
DK505588D0 (da) *	1988-02-26	1988-09-09	Jesper Hamburger	Middel og anvendelse af samme
DK191889D0 (da) *	1989-04-20	1989-04-20	Bukh Meditec	Kosmetisk middel
US5618798A (en) *	1989-04-20	1997-04-08	Bar-Shalom; Daniel	Use of sucralfate to treat baldness
FR2646604B1 (fr)	1989-05-03	1994-02-04	Fabre Medicament Pierre	Composition pour usage externe a base de sucralfate et son procede de preparation
DK86492D0 (da)	1992-06-30	1992-06-30	Bukh Meditec	Laegemiddel
US7795239B2 (en) *	1992-07-27	2010-09-14	Mueller Medical International LLC	Saccharide compositions and method of use
WO2006017752A2 (en) *	2004-08-05	2006-02-16	Ivax Corporation	Sulfated oligosaccharides
FR2916355B1 (fr)	2007-05-25	2009-08-28	Urgo Soc Par Actions Simplifie	Nouveau principe actif dans la cicatrisation et son utilisation

2011
- 2011-05-31 FR FR1154752A patent/FR2975993B1/fr active Active
2012
- 2012-05-31 US US14/123,071 patent/US9562065B2/en active Active
- 2012-05-31 EP EP12724633.8A patent/EP2714705B1/fr active Active
- 2012-05-31 PT PT127246338T patent/PT2714705E/pt unknown
- 2012-05-31 JP JP2014513184A patent/JP5998211B2/ja active Active
- 2012-05-31 PL PL12724633T patent/PL2714705T3/pl unknown
- 2012-05-31 ES ES12724633.8T patent/ES2541476T3/es active Active
- 2012-05-31 WO PCT/EP2012/060211 patent/WO2012163997A1/fr not_active Ceased

Also Published As

Publication number	Publication date
JP5998211B2 (ja)	2016-09-28
US9562065B2 (en)	2017-02-07
PT2714705E (pt)	2015-08-05
WO2012163997A1 (fr)	2012-12-06
US20140121180A1 (en)	2014-05-01
EP2714705A1 (fr)	2014-04-09
FR2975993B1 (fr)	2013-06-28
PL2714705T3 (pl)	2015-09-30
EP2714705B1 (fr)	2015-04-22
FR2975993A1 (fr)	2012-12-07
JP2014515388A (ja)	2014-06-30

Publication	Publication Date	Title
US9629856B2 (en)	2017-04-25	Compositions and methods for the treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds
ES2521065T3 (es)	2014-11-12	Composiciones tópicas para conservar o restaurar la integridad de las mucosas
ES3029362T3 (en)	2025-06-24	Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same
ES2856480T3 (es)	2021-09-27	Utilizaciones cosméticas de la swertiamarina
ES2661908T3 (es)	2018-04-04	Asociación sinérgica de la alanina-glutamina, el ácido hialurónico y un extracto de avena y su utilización en una composición destinada a la cicatrización y la reparación de las lesiones cutáneas
ES2408342T3 (es)	2013-06-20	Uso de osmolitos obtenidos a partir de bacterias extremófilas para la preparación de fármacos para el tratamiento externo de neurodermatitis
JP5685315B2 (ja)	2015-03-18	ニコチン酸アデニンディヌクレオチドリン酸又はその誘導体を含む薬学又は化粧料組成物
TW201628614A (zh)	2016-08-16	活化長壽基因的組合物
WO2017009486A1 (en)	2017-01-19	Topical compositions
ES2827253T3 (es)	2021-05-20	Preparación cutánea externa antienvejecimiento
JP6822648B2 (ja)	2021-01-27	トリプターゼ阻害剤組成物
ES2606233T3 (es)	2017-03-23	Composiciones para el tratamiento de la rosácea que comprende quitosano y una amida de ácido dicarboxílico
PT2004235E (pt)	2010-06-11	Composição para uso cosmético ou farmacêutico-dermatológico
KR102233647B1 (ko)	2021-03-30	피부 재생 또는 상처 치료용 펩타이드 aec1d 및 이의 용도
JP6578323B2 (ja)	2019-09-18	フィラグリン産生促進剤
EP2714706A1 (fr)	2014-04-09	Sucroses octasulfates de calcium, leur préparation et leurs applications pharmaceutiques et cosmétiques
JP5998211B2 (ja)	2016-09-28	マグネシウムのスクロースオクタ硫酸エステル、その製造方法およびその医薬的および美容的使用
KR102917114B1 (ko)	2026-01-26	테스트리올리에이트(TES Trioleate) 및 올레아마이드 설린올(Oleamide Serinol)을 유효성분으로 포함하는 세포노화 완화 및 예방용 조성물
US11773081B2 (en)	2023-10-03	Pharmaceutical composition for preventing or treating wound, comprising indirubin derivative as active ingredient
ES2893278T3 (es)	2022-02-08	Uso de derivados del ácido salicílico como agente activo prodescamante
JP7690469B2 (ja)	2025-06-10	ヒアルロン酸産生促進剤およびコラーゲン産生促進剤
KR102233646B1 (ko)	2021-03-30	피부 재생 또는 상처 치료용 펩타이드 aes11-1 및 이의 용도